New Randomized Trial Shows Alcat-Guided Diets Outperform a Sham Diet in IBS

A double-blind, sham-controlled study from Sheba Medical Center found that patients following a personalized, immune-guided elimination diet had significantly greater symptom improvement than patients on a matched sham diet.

Research note: This trial was funded by Cell Science Systems, which markets Alcat testing and was acquired by Genova Diagnostics in January 2026. The funder had no role in study design, data collection, or analysis, and the acquisition took place after the trial was conducted.

Irritable bowel syndrome (IBS) is notoriously hard to treat with diet alone. Patients are often told to try broad restriction - low-FODMAP, gluten-free, dairy-free - with mixed results and real risk of over-restriction. A new randomized controlled trial from the Gastroenterology Institute at Sheba Medical Center offers clinical evidence that a personalized, immune-guided approach may work better than generic elimination.1

Published in Gastroenterology Report in 2026, it's the largest double-blind, sham-controlled trial of an Alcat-guided elimination diet to date, and it builds on an earlier, smaller Yale-affiliated IBS trial that first tested this approach.12

Why Another IBS Diet Trial Matters

Food-related symptoms are extremely common in IBS - most patients report that meals trigger or worsen their symptoms but broad, multi-food restriction diets are hard to sustain and can compromise nutritional adequacy and quality of life. That's the clinical problem this trial was designed to address: does narrowing the elimination list to foods identified through leukocyte activation testing outperform a diet that looks and feels similarly restrictive, but isn't matched to the individual patient's results?1

Study Design

A note on terminology: A sham control is a comparison arm designed to look and feel like the active intervention - similar in structure and restrictiveness - without the specific element being tested. It's the dietary equivalent of a placebo pill or sham surgery, used to isolate whether the personalized element itself, not just the experience of following a structured diet, drives the outcome.

Researchers at Sheba Medical Center in Ramat Gan, Israel, enrolled 68 patients with IBS with predominant diarrhea or mixed bowel habits (IBS-D/M) between August 2020 and April 2022.1 In a double-blind, sham-controlled design, patients were randomized to either:

• An Alcat-guided diet, eliminating foods identified as reactive on leukocyte activation testing, or
• A sham-balanced diet, structurally similar in restrictiveness but not matched to the patient's own test results.1

Neither patients nor the clinicians assessing outcomes knew which diet a given patient had been assigned, and the trial ran for eight weeks. The primary outcome was a 50-point or greater reduction on the IBS Symptom Severity Scale (IBS-SSS), a validated, widely used measure of symptom burden. Secondary and exploratory outcomes included the IBS Global Improvement Scale (IBS-GIS) and a simple positive/negative response classification.1

What The Trial Found

The results favored the Alcat-guided diet across every outcome measured:

Primary Outcomes: 85.7% of patients on the Alcat-guided diet achieved a clinically meaningful reduction in symptom severity, compared with 54.5% on the sham diet (P = 0.005).

Global Improvement: 74.3% of the Alcat group reported meaningful global improvement, versus 42.4% of controls (P = 0.008).

Positive Responce 85.7% of the Alcat group were classified as positive responders, compared with 57.6% of the sham group (P = 0.010).

Because the Alcat group started with a somewhat higher baseline symptom severity score than the sham group, the researchers also re-analyzed a balanced sub-cohort matched for baseline severity. The advantage held: 90% of Alcat patients versus 59% of controls met the primary outcome in this matched analysis.

Importantly, the trial reported no serious adverse events, supporting the diet's safety profile over the eight-week intervention.1

How This Builds on the Earlier Yale Trial

This isn't the first sham-controlled trial of an Alcat-guided diet. A 2017 Yale-affiliated trial of 58 IBS patients found similar directional benefit - greater improvement in global symptom and severity scores among patients following diets matched to their leukocyte activation results, compared with a mismatched sham diet. That trial did not show significant differences on every secondary endpoint, and its authors urged cautious interpretation.2

The new Sheba trial adds weight in three ways: a comparably sized but more contemporary cohort, a formal double-blind sham design, and effect sizes on the primary outcome that were larger and reached tighter statistical significance. Two independent research teams, using independent cohorts, have now reported the same directional result in blinded, sham-controlled conditions.

Clinical Translation

For clinicians working with IBS patients, the practical question is rarely "does diet matter" - most patients already believe it does. The harder question is which foods to remove, for how long, and how to avoid turning a therapeutic trial into permanent, unnecessary restriction.

Why This Matters Clinically

This trial's design directly addresses that question: both groups followed a similarly structured, comparably restrictive diet. The only difference was whether the restricted foods were the ones identified by the patient's own leukocyte activation results.1 That the personalized group outperformed the sham group suggests the specific foods identified - not just the act of following a structured elimination diet - were doing meaningful clinical work.

Reading the Study Carefully

A couple of methodological points are worth noting for anyone evaluating the strength of this evidence:

• Baseline Imbalance: The Alcat group started with higher symptom severity scores than controls. The researchers accounted for this with a matched sub-cohort analysis, which preserved the effect size and significance.1
• Population Studied: The trial enrolled patients with IBS-D and IBS-M specifically; it does not speak directly to IBS-C (constipation-predominant) or to non-IBS food-sensitivity presentations.1
• What Alcat Still Doesnt Do: As with any leukocyte activation test, Alcat does not diagnose IgE-mediated food allergy, celiac disease, or enzyme-based intolerances, and it shouldn't replace conventional workup when alarm symptoms are present.

The Bottom Line

This trial replicates, in a larger and more rigorously blinded design, what the earlier Yale-affiliated study first suggested: personalizing an elimination diet to a patient's own leukocyte activation results appears to outperform a comparably restrictive, non-personalized diet in IBS. Combined with mechanistic work showing measurable innate immune activation in leukocyte-activation-positive foods, the evidence base for Alcat-guided elimination diets in IBS now includes two independent sham-controlled trials plus supporting mechanistic biology.

For clinicians, that combination - replicated clinical outcome data plus biological plausibility - is what moves a tool from 'interesting idea' to a defensible part of a personalized nutrition strategy for selected IBS patients.

---